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Abstract Topiroxostat, a selective xanthine oxidoreductase
inhibitor, is used in Japan for the treatment of hyperuricemic
patients with or without gout. In terms of the effectiveness of
topiroxostat in lowering serum urate levels, the dose–response
relationship has been evaluated; however, it remains to be
verified. A randomized, multi-center, double-blinded study
of topiroxostat was performed for Japanese hyperuricemic
patients with or without gout. During the 16-week study,
157 Japanese hyperuricemic patients with or without gout
were randomly assigned to receive a placebo, topiroxostat at
120 or 160 mg/day, or allopurinol at 200 mg/day. The primary
endpoint of this study was to determine the lowering rate of
serum uric acid levels compared to those of baseline at the end
of administration. A dose–response relationship (regarding
decreases in the serum urate levels) was confirmed for the
placebo and topiroxostat at 120 and at 160 mg/day.
Moreover, at the end of administration, the lowering rate of
serum urate levels was determined to be −44.8% in the
topiroxostat 160-mg/day group. No significant difference in
the incidence of adverse events was observed among all
groups, including the allopurinol group. The serum urate-
lowering effect of topiroxostat was found to have a dose–
response relationship in Japanese hyperuricemic patients with
or without gout.
Keywords Gout . Hyperuricemia . Late phase 2 clinical
study . Topiroxostat . Xanthine oxidoreductase inhibitor
Introduction
Hyperuricemia [defined by a serum urate concentration
≥416.4 μmol/L (or ≥7.0 mg/dL) in Japan] is a causative factor
of urate deposition disease (e.g., urolithiasis and gouty arthri-
tis). From the perspective of gout prevention, the main goal of
hyperuricemia treatment is to lower serum urate levels and to
maintain the levels at ≤356.9 μmol/L (or ≤6.0 mg/dL) [1–3].
Meanwhile, in recent years, hyperuricemia has been found to
cause renal impairment and to be associated with the onset and
progression of chronic kidney disease (CKD) [4–6]. Several
interventional studies have suggested that serum urate-
lowering agents, such as allopurinol, effectively maintain re-
nal function in CKD [7, 8]. For asymptomatic hyperuricemia,
in cases with underlying diseases, such as hypertension, ische-
mic heart disease, and kidney disease, serum urate levels of
≥475.8 μmol/L (or 8.0 mg/dL) have been established as the
criteria for the introduction of pharmacotherapy in Japan [1].
Allopurinol [a hypoxanthine-analog xanthine oxidoreduc-
tase (XOR) inhibitor] is a serum urate-lowering agent widely
used throughout the world. However, side effects, such as
allergies and liver impairment, and even severe rash associat-
ed with myelosuppression and necrosis have been reported,
albeit rarely. Furthermore, since allopurinol and its active me-
tabolite oxipurinol are mainly excreted via the kidneys, there
is a concern among patients with impaired renal function that
they may cause an elevation in serum oxipurinol levels,
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thereby causing a higher incidence of side effects. Therefore,
the dosage should be regulated [9–11].
Topiroxostat (formerly known as FYX-051) is a non-
purine selective XOR inhibitor [12–14]. Unlike chemical
structure-based XOR inhibitors (e.g., febuxostat), topiroxostat
is a hybrid-type inhibitor that not only has a chemical
structure-based XOR inhibitory action but also binds cova-
lently to molybdenum in the active center during the
enzyme-induced hydroxylation process [12, 13]. In addition,
the pharmacokinetics of unchanged topiroxostat or its metab-
olites is unaffected bymild-to-moderate renal impairment, and
in patients with concurrent moderate renal impairment and
hyperuricemia, it has been reported to lower the serum urate
levels and urinary albumin levels [15].
The present study was performed to evaluate and verify the
serum urate-lowering effects, the dose–response relationship
in terms of serum urate reduction, and the safety of
topiroxostat in hyperuricemic patients with or without gout.
Materials and methods
Study design
The present study was performed to verify the dose–response
relationship and optimal dose of topiroxostat for lowering se-
rum urate levels. Before the start of the study, the institutional
review board of each participating institution provided approv-
al after reviewing the study content. Furthermore, this study
was conducted in accordance with the Declaration of
Helsinki, Good Clinical Practice guidelines, and other relevant
regulations. Written informed consent was obtained from all
study participants prior to the start of the pre-observation peri-
od, after providing a thorough explanation of the study content.
This study is a phase 2, multi-center, randomized, placebo-
controlled, double-blind verification study. Fourteen clinical
institutions of Japan participated in the study.
Patients were randomly assigned to either placebo,
topiroxostat 120/160-mg, or allopurinol 200-mg daily group
(ratio 1:1:1:1). The allopurinol arm was also set up as a refer-
ence to examine the effectiveness, safety, and incidence of
gouty arthritis. To minimize the risk of gouty arthritis devel-
oping as a result of a sudden reduction in serum urate levels
[16], the dose titration method was used. The dosage scheme
is shown in Fig. 1. This study consisted of a run-in period (1 to
4 weeks) and a treatment period (initial phase I, 2 weeks;
initial phase II, 4 weeks; maintenance phase, 10 weeks).
In the event that patients had been receiving therapy with
drugs thought to affect serum urate levels prior to enrollment,
the patients were enrolled after a washout period of at least
2 weeks. To reduce the difference between groups according
to patient attributes, dynamic allocation was used. Factors
taken into consideration for dynamic allocation included
Bmedical institution participating in the study,^ Bserum urate
level (value measured on the closest day to the start of
treatment),^ and Bthe presence or absence of a history of gouty
arthritis.^
For the classification of hyperuricemia, based on urate
measurement in the 60-min urine collection during the run-
in period, we classified patients into the following four types:
(1) patients with urinary excretion of urate (EUA; mg/kg/h)
>0.51 and urate clearance (CUA; mL/min) ≥7.2 were defined
as Burate-overproduction type,^ (2) patients with EUA <0.48
or CUA <7.2 were defined as Burate-underexcretion type,^ (3)
patients with EUA >0.51 and CUA <7.2 were defined as
Bcombined type,^ and (4) patients with 0.48 ≤ EUA ≤0.51
and CUA ≥7.2 were defined as Bnormal type^.
Inclusion and exclusion criteria
Patients were included in this study if they met the following
inclusion criteria: Japanese patients aged 20 to 64 years who
were able to provide consent in writing, with serum urate level
in the run-in period of ≥416.4 μmol/L in patients with tophi or
a history of gout attacks or ≥535.4 μmol/L in patients with
hyperuricemia (however, ≥475.8 μmol/L in patients whowere
receiving treatment for or had a diagnosis of urolithiasis, hy-
pertension, hyperlipidemia, or diabetes).
Patients were excluded from the study if they met the fol-
lowing exclusion criteria: the onset of gouty arthritis within
2 weeks prior to the start of the study drug administration;
primary or secondary hyperuricemia that occurs secondary
to specific disorders, including Lesch–Nyhan syndrome, he-
matologic malignancies, or Down’s syndrome; HbA1c ≥8.0%
or poorly controlled hyperglycemia; renal function impair-
ment (eGFR ≥50 mL/min/1.73 m2); liver impairment (ALT
≥100 U/L and/or AST ≥100 U/L), severe hypertension (sys-
tolic blood pressure ≥180 mmHg and/or diastolic blood pres-
sure ≥110 mmHg or poorly controlled condition with hypo-
tensive agent); and the use of urate-lowering agents, azathio-
prine, 6-mercaptoprine, theophylline, the study drug other
than topiroxostat, or agents thought to affect the outcomes
during the period from 2 weeks prior to the start of the pre-
observation period until the day of treatment commencement.
Blinding
The individuals responsible for allocating the study drug per-
formed all allocations and managed the allocation table (in-
cluding study drug distribution). Furthermore, to maintain the
double-blind condition, serum urate levels measured after ad-
ministration of the study drug were concealed from the phy-
sician responsible for the treatment, the patients, and study
applicants throughout the study period.
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Endpoints
The primary efficacy endpoint was the serum urate reduction
rate from baseline values upon the final visit. The secondary
endpoint was the achievement rate of serum urate level
≤356.9 μmol/L, etc., upon the final visit. In addition, for lab-
oratory tests, samples were collected from each institution,
and measurements were managed in an integrated manner.
Safety evaluations
Any adverse events (AEs) and safety assessments conducted
by clinical investigators, including vital signs, 12-lead electro-
cardiography, clinical laboratory tests, and clinical examina-
tions, were recorded during the study period. AEs were clas-
sified according to system organ class and preferred term
(MedDRA/J version 13.0) and were evaluated in terms of their
potential relationship with the study drug and severity.
Furthermore, patients who developed severe AEs
discontinued the treatment. To evaluate the incidence of gouty
arthritis, preventive administration of colchicine was not per-
mitted during the pre-observation and the double-blind test
period.
Statistical analyses
In this study, the primary endpoint was the serum urate-
lowering rate, which was analyzed by examining dose respon-
siveness of the serum urate-lowering rates using the
Jonckheere–Terpstra test. To achieve this, the number of pa-
tients who gave the Jonckheere–Terpstra test detection power
of 80% or above was used as the target number of patients to
calculate the rates. In other words, on the basis of the results of
the two phase 2 (2a) trials, in this study, the serum urate-
lowering rates of each topiroxostat treatment group (placebo
group, 120-mg group, and 160-mg group) were expected to be
0, 39, and 47%, respectively, with an assumed standard devi-
ation of 9%, and when calculating the number of patients in
the dose–response study according to a simulation with a 5%
level of significance and detection power of 80%, there were
three patients per group. Taking into consideration the number
of patients who may be excluded from the analysis and the
number of patients in whom safety could be evaluated, we set
the target number of patients as 40 patients per group.
Analysis sets for efficacy included the per protocol set
(PPS) and full analysis set (FAS), the latter consisting of all
the randomized patients who received at least one dose of
the study drug and underwent serum urate measurement
during at least one visit, and primary analyses were per-
formed for the FAS. To impute the missing value of serum
urate levels, the modified last observation carried forward
was used; if the serum urate data at week 16 was missed,
the data at week 14 was used as the final-visit data. The
approach was pre-specified before the start of the study.
The χ2 test was used for testing the secondary efficacy
endpoint, and Bonferroni correction was used to avoid the
multiplicity of testing. Cochran–Armitage test was used for
the evaluation of dose dependency of the secondary efficacy
endpoint. In addition, we performed a pre-specified sub-group
analysis of the primary efficacy endpoint by the classification
of hyperuricemia.
Safety analyses were performed on the safety population,
which consisted of all the patients who took at least one dose
of the study drug. The incidences of AEs were summarized in
the number and proportion of patients.
Statistical analyses were performed using the software
Statistical Analysis System release 8.2 (SAS Institute, Cary,
NC, USA). Unless otherwise stated, data are shown as
mean ± standard deviation (SD). The level of significance of
a two-tailed test was set at a P value of 5% (2.5% one way).
However, for comparisons of patient attributes, a two-tailed P
value of 15% was considered significant.
Fig. 1 Study schema. aIn this case, patients had been prescribed urate-lowering agents or agents affecting the serum urate level
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Results
Participant details
In this study, 223 patients signed the informed consent. A
breakdown of study participants is shown in Fig. 2. The study
drug was randomly allocated to 157 patients in 14 participat-
ing institutions (placebo group 39 patients, topiroxostat 120-
mg group 39 patients, topiroxostat 160-mg group 40 patients,
and allopurinol group 39 patients). The study treatment was
completed by 34 patients in the placebo group, 39 patients in
the topiroxostat 120-mg group, 39 patients in the topiroxostat
160-mg group, and 38 patients in the allopurinol group. The
treatment was discontinued by five patients in the placebo
group, zero patient in the topiroxostat 120-mg group, one
patient in the topiroxostat 160-mg group, and one patient in
the allopurinol group. Analysis of safety was performed for all
157 cases but that of efficacy was performed for 156 cases,
since one case, whose emergency key had been broken before
finalizing the CRF, was excluded.
Patient attributes
Patient attributes for FAS are shown in Table 1.
The 156 patients constituting the FAS included 153males and
3 females. The patient age was 51.4 ± 8.2 years (mean ± SD),
with a height of 169.90 ± 6.63 cm, weight of 74.92 ± 11.51 kg,
the duration of hyperuricemia of 11.74 ± 8.43 years, and serum
urate level of 540.1 ± 79.7 μmol/L.
The bias in distribution between treatment groups was ob-
served in age (Kruskal–Wallis test P = 0.114) and in height
(Kruskal–Wallis test P = 0.016).
Efficacy
Figure 3 shows the analysis results of the FAS for serum urate-
lowering rate upon the final visit, which was the primary end-
point. The serum urate-lowering rate ± SD of the placebo
group, topiroxostat 120-mg group, topiroxostat 160-mg
group, and allopurinol group upon the final visit were
3.93 ± 11.39, 40.92 ± 9.84, 44.79 ± 13.26, and
40.18 ± 10.30%, respectively, indicating a significant urate-
lowering rate in the topiroxostat 120-mg group, the
topiroxostat 160-mg group, and the allopurinol group com-
pared to that in the placebo group (Tukey’s test P < 0.001).
Furthermore, dose responsiveness was observed in the serum
urate-lowering action in the placebo group and the
topiroxostat 120- and 160-mg groups (Jonckheere–Terpstra
test P < 0.001).
The serum urate levels for the FAS at each point in time
(prior to treatment and at 2, 6, 10, 14, and 16 weeks of treat-
ment) are shown in Fig. 4. Thus, a serum urate-lowering effect
Fig. 2 Flow diagram of the study
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was observed with each dosage of the topiroxostat groups as
well as in the allopurinol group compared to baseline values
before administration.
The achievement rates of the serum urate level
≤356.9 μmol/L upon the final visit in the FAS are shown in
Table S1. Upon the final visit, serum urate level of
≤356.9 μmol/L was achieved by 0/35 patients (0.0%) in the
placebo group, 30/39 patients (76.9%) in the topiroxostat 120-
mg group, 30/39 patients (76.9%) in the topiroxostat 160-mg
group, and 32/38 patients (84.2%) in the allopurinol group. In
addition, the placebo group, the topiroxostat 120-mg group,
and the topiroxostat 160-mg group, in which the achievement
rates of serum urate levels ≤356.9 μmol/L were obtained,
exhibited a dose–response relationship (Cochran–Armitage
test P < 0.001). Furthermore, independency between each
treatment group and each achievement rate was dismissed
(independency test P < 0.001). Although a significant differ-
ence was observed between the placebo group and the
topiroxostat 120-mg group, the placebo group and the
topiroxostat 160-mg group, and the placebo group and the
allopurinol group (χ2 test P < 0.001), no significant difference
was observed between the topiroxostat 120- and 160-mg
groups, the topiroxostat 120-mg group and allopurinol group,
and the topiroxostat 160-mg group and the allopurinol group
(χ2 test P = 1.000, P = 0.420, and P = 0.420). Proportion of
subjects whose serum urate level ≤297.4 μmol/L are also
shown in Table S1. Because these data are not the pre-
specified secondary endpoint, the data are shown as a result
of post hoc analysis without statistics. Upon the final visit,
serum urate level of ≤297.4 μmol/L was achieved by 0/35
patients (0.0%) in the placebo group, 15/39 patients (38.5%)
in the topiroxostat 120-mg group, 23/39 patients (59.0%) in
the topiroxostat 160-mg group, and 11/38 patients (28.9%) in
the allopurinol group.
Amount of change in serum urate level was also shown in
Table S2. For FAS, the amount of change in serum urate levels
at the final visit from the level at baseline in each group (pla-
cebo group, topiroxostat 120- and 160-mg groups, and allo-
purinol group) (mean ± SD)were −22.4 ± 63.6, −220.8 ± 64.7,
−243.0 ± 82.1, and −226.7 ± 84.9 μmol/L, respectively. A
significant difference was observed between topiroxostat
120-mg group and placebo group, topiroxostat 160-mg group
and placebo group, and also allopurinol group and placebo
group (Tukey’s test P < 0.001).
Safety
Among the AEs observed in this study, with regards to ad-
verse effects for which a causal relationship could not be de-
nied, the number of patients with/incidence of adverse effects
including gouty arthritis was 15/39 patients (38.5%) in the
placebo group, 8/39 patients (20.5%) in the topiroxostat
Fig. 3 Percent reduction from baseline in serum urate level at the final
visit (FAS)
Fig. 4 Time-course plots of
serum urate level at each time
point (FAS). Mean ± SD.
*P < 0.05 (vs. 0 W). To convert
serum urate levels fromμmol/L to
mg/dL, divide by 59.48
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120-mg group, 7/40 patients (17.5%) in the topiroxostat 160-
mg group, and 10/39 patients (25.6%) in the allopurinol
group, with a significant difference observed between the pla-
cebo group and the topiroxostat 160-mg group (χ2 test
P = 0.038). Moreover, the number of patients with/incidence
of adverse effects excluding gouty arthritis was 13/39 patients
(33.3%) in the placebo group, 6/39 patients (15.4% in the
topiroxostat 120-mg group, 6/40 patients (15.0) in the
topiroxostat 160-mg group, and 7/39 patients (17.9%) in the
allopurinol group, with no significant difference observed for
any group (χ2 test) (Table 2).
Severe AEs which occurred during the study included one
case of death (suicide) (allopurinol group) and one case of left
nephrolithiasis (placebo group). The former case was attribut-
ed to family relationship problems, and the attending physi-
cian rejected a causal relationship. For the latter case, the
attending physician determined that the renal stones had al-
ready developed prior to the start of treatment with the study
drug, and thus, a causal relationship was rejected. The severity
of all other AEs and adverse effects were mild to moderate.
In this study, the number of patients with/incidence of
gouty arthritis in each group was 3/39 patients (7.7%) in the
placebo group, 2/39 patients (5.1%) in the topiroxostat 120-
mg group, 2/40 patients (5.0%) in the topiroxostat 160-mg
group, and 4/39 patients (10.3%) in the allopurinol group.
There were no clinically relevant changes in vital signs and
12-lead ECG.
Discussion
In the present study, we confirmed and verified dose–response
relationship for placebo and topiroxostat at 120- and 160-mg
doses regarding the percent change in serum urate level from
baseline to the final visit as the primary efficacy endpoint, and
we also determined the percentage of patients with serum
urate level ≤356.9 μmol/L at the final visit, as the secondary
efficacy endpoint. In addition, as a result of prescribed sub-
group analysis by the classification of hyperuricemia,
topiroxostat may have serum urate-lowering efficacy beyond
the classification of hyperuricemia (urate-overproduction type
and urate-underexcretion type).
For safety, the majority of AEs were mild to moderate, with
comparable incidences among all treatment groups. However,
further long-term studies are needed to obtain more data with
regards to the safety profile of topiroxostat according to the
actual status of the use of therapeutic agents for
hyperuricemia.
The prevention of gouty arthritis is one important goal in
treatment to lower serum urate levels [1]. However, adminis-
tration of XOR inhibitors rapidly reduces serum urate levels,
particularly at the start of treatment [17], which sometimes
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the risk of gouty arthritis onset during the topiroxostat treat-
ment period. For this reason, the preventive use of colchicine
was not permitted. Instead, the dose titration method was
employed to administer the study drug. This method is recom-
mended in Japan in the treatment of hyperuricemia from the
perspective that it can avoid the onset of gouty arthritis caused
by a sudden drop in serum urate levels. The number of patients
with/incidence of gouty arthritis was low in this trial, with 3/39
patients (7.7%) in the placebo group, 2/39 patients (5.1%) in the
topiroxostat 120-mg group, 2/40 patients (5.0%) in the
topiroxostat 160-mg group, and 4/39 patients (10.3%) in the
allopurinol group. Furthermore, the pharmacokinetics of
topiroxostat is unaffected bymild-to-moderate renal impairment,
and therefore, there is no need to adjust the administration route
or dosage in patients with moderate renal impairment [15]. This
is a clinically significant difference compared to allopurinol.
This study demonstrated the dose–response relationship for
the placebo and topiroxostat at doses of 120 and 160 mg for
serum urate-lowering rate upon the final visit, with no safety
problems. Furthermore, the serum urate-lowering rate upon
the final visit of allopurinol, a congener agent with compara-
ble effects, set as a comparative reference, and the achieve-
ment rate of serum urate levels <356.9 μmol/L upon the final
visit should be taken into consideration, and we believe that a
controlled comparative trial of allopurinol should be per-
formed with topiroxostat at 120 mg.
Acknowledgments We are grateful to the investigators, local study
coordinators, and the patients for their valuable contributions to these
studies. Fuji Yakuhin Co., Ltd. sponsored this study.
Compliance with ethical standards
Conflict of interest TH has received consultant fees and/or speakers’
honoraria from Fuji Yakuhin Co., Ltd., the manufacturer of topiroxostat.
TS and TO were employees of Fuji Yakuhin Co., Ltd. at the time of the
study.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a link
to the Creative Commons license, and indicate if changes were made.
References
1. Li-Yu J, Clayburne G, Sieck M, Beutler A, Rull M, Eisner E,
Schumacher HR Jr (2001) Treatment of chronic gout. Can we
determine when urate stores are depleted enough to prevent attacks
of gout? J Rheumatol 28:577–580
2. Shoji A, Yamanaka H, Kamatani N (2004) A retrospective study of
the relationship between serum urate level and recurrent attacks of
gouty arthritis: evidence for reduction of recurrent gouty arthritis
with antihyperuricemic therapy. Arthritis Rheum 51:321–325
3. Sarawate CA, Patel PA, Schumacher HR, Yang W, Brewer KK,
Bakst AW (2006) Serum urate levels and gout flares: analysis from
managed care data. J Clin Rheumatol 12:61–65
4. Iseki K, Oshiro S, Tozawa M, Iseki C, Ikemiya Y, Takishita
S (2001) Significance of hyperuricemia on the early detec-
tion of renal failure in a cohort of screened subjects.
Hypertens Res 24:691–697
5. Obermayr RP, Temml C, Gutjahr G, Knechtelsdorfer M, Oberbauer
R, Klauser-Braun R (2008) Elevated uric acid increases the risk for
kidney disease. J Am Soc Nephrol 19:2407–2413
6. Weiner DE, Tighiouart H, Elsayed EF, Griffith JL, Salem DN,
Levey AS (2008) Uric acid and incident kidney disease in the
community. J Am Soc Nephrol 19:1204–1211
7. Siu YP, Leung KT, Tong MK, Kwan TH (2006) Use of allopurinol
in slowing the progression of renal disease through its ability to
lower serum uric acid level. Am J Kidney Dis 47:51–59
8. Goicoechea M, de Vinuesa SG, Verdalles U, Ruiz-Caro C,
Ampuero J, Rincón A, Arroyo D, Luño J (2010) Effect of allopu-
rinol in chronic kidney disease progression and cardiovascular risk.
Clin J Am Soc Nephrol 5:1388–1393
9. Arellano F, Sacristán JA (1993) Allopurinol hypersensitivity syn-
drome: a review. Ann Pharmacother 27:337–343
10. Emmerson BT, Gordon RB, Cross M, Thomson DB (1987) Plasma
oxipurinol concentrations during allopurinol therapy. Br J
Rheumatol 26:445–449
11. Hande KR, Noone RM, Stone WJ (1984) Severe allopurinol toxic-
ity. Description and guidelines for prevention in patients with renal
insufficiency. Am J Med 76:47–56
12. Okamoto K, Matsumoto K, Hille R, Eger BT, Pai EF, Nishino T
(2004) The crystal structure of xanthine oxidoreductase during ca-
talysis: implications for reactionmechanism and enzyme inhibition.
Proc Natl Acad Sci U S A 101:7931–7936
13. Matsumoto K, Okamoto K, Ashizawa N, Nishino T (2011) FYX-
051: a novel and potent hybrid-type inhibitor of xanthine oxidore-
ductase. J Pharmacol Exp Ther 336:95–103
14. Sato T, Ashizawa N,Matsumoto K, Iwanaga T, Nakamura H, Inoue
T, Nagata O (2009) Discovery of 3-(2-cyano-4-pyridyl)-5-(4-pyri-
dyl)-1,2,4-triazole, FYX-051—a xanthine oxidoreductase inhibitor
for the treatment of hyperuricemia [corrected]. Bioorg Med Chem
Lett 19:6225–6229
15. Hosoya T, Ohno I, Nomura S, Hisatome I, Uchida S, Fujimori S,
Yamamoto T, Hara S (2014) Effects of topiroxostat on the serum
urate levels and urinary albumin excretion in hyperuricemic stage 3
chronic kidney disease patients with or without gout. Clin Exp
Nephrol 18:876–884
16. Yamanaka H, Togashi R, Hakoda M, Terai C, Kashiwazaki S, Dan
T, Kamatani N (1998) Optimal range of serum urate concentrations
to minimize risk of gouty attacks during anti-hyperuricemic treat-
ment. Adv Exp Med Biol 431:13–18
17. Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA,
Eustace D, Palo WA, Streit J, Joseph-Ridge N (2005) Febuxostat
compared with allopurinol in patients with hyperuricemia and gout.
N Engl J Med 353:2450–2246
656 Clin Rheumatol (2017) 36:649–656
